Table 3.
On-demand therapies and long-term prophylaxes used by the patients after the primary vaccination cycle.
| On-Demand Therapy | HAE (n = 185) | AAE (n = 23) |
|---|---|---|
| Icatibant; n (%) | 123 (66.5%) | 15 (65.2%) |
| Plasma-derived C1-INH (Berinert® by CSL Behring); n (%) | 91 (49.2%) | 8 (34.8%) |
| Tranexamic acid; n (%) | 9 (4.9%) | - |
| Long-term prophylaxis | ||
| No long-term prophylaxis; n (%) | 102 (55.1%) | 14 (61%) |
| Tranexamic acid; n (%) | 2 (1.1%) | 5 (21.8%) |
| Danazol; n (%) | 30 (16.3%) | 1 (4.3%) |
| Lanadelumab; n (%) | 37 (20%) | 2 (8.6%) |
| Experimental †; n (%) | 1 (0.5%) | - |
| Plasma-derived C1-INH (Berinert® by CSL Behring); n (%) | 3 (1.6%) | 1 (4.3%) |
| Plasma-derived C1-INH (Cinryze® by Takeda); n (%) | 10 (5.4%) | - |
† Intended as berotralstat, used for compassionate use.